CRASH-II

CRASH-II remains the landmark trial upon which ubiquitous delivery of tranexamic acid to trauma patients is based. Yet the study is not without its controversy.

From an inescapable conflict of interest, to a mortality difference which seems disproportionate to the magnitude of the rhetoric surrounding this work, it remains unclear to what extent TXA should be used in traumatic hemorrhage.

What are your thoughts on the CRASH-II study? Feel free to draw on the paper, as well as our presentation, which is posted under “Previous Meetings” in your reply.